Fbio stock forecast incorporates sector-wide biotech data

FBIO stock forecast incorporates sector-wide biotech data, noting that FDA approval cycles remain a key catalyst; several Fortress Biotech drug trials expected in late 2024 could move the needle quickly. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FBIO at https://www.zacks.com/ap/FBIO However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies. Quant-driven FBIO stock forecast simulations show a 60% chance of exceeding $3 in Q3 2024, assuming volatility remains within the current 35–40% annualized band.